Choosing drugs for UK COVID-19 treatment trials.

Chinnery, Patrick F; Bonnet, Marion; Cave, Alison; Hofer, Matthias P; Lamb, Alastair; McConkey, Glenn A; Medcalf, Nicholas; Smith, Stephen P; Tsakok, Teresa; Watson, Robert; Webster, Steve; You, Tao

Chinnery, Patrick F; Bonnet, Marion; Cave, Alison; Hofer, Matthias P; Lamb, Alastair; McConkey, Glenn A; Medcalf, Nicholas; Smith, Stephen P; Tsakok, Teresa; Watson, Robert; Webster, Steve; You, Tao.

Nat Rev Drug Discov ; 21(2): 81-82, 2022 02.

Article in English | MEDLINE | ID: covidwho-1683945

Subject(s)

COVID-19 Drug Treatment; Clinical Trials as Topic/methods; Drug Development/methods; Clinical Trials as Topic/economics; Drug Development/economics; Financing, Government; Humans; Research Support as Topic; United Kingdom

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Clinical Trials as Topic / Drug Development / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Nat Rev Drug Discov Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google